CA2288171A1 - Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs - Google Patents
Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs Download PDFInfo
- Publication number
- CA2288171A1 CA2288171A1 CA002288171A CA2288171A CA2288171A1 CA 2288171 A1 CA2288171 A1 CA 2288171A1 CA 002288171 A CA002288171 A CA 002288171A CA 2288171 A CA2288171 A CA 2288171A CA 2288171 A1 CA2288171 A1 CA 2288171A1
- Authority
- CA
- Canada
- Prior art keywords
- amine
- phenyl
- phthalazin
- disorders
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 10
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title description 2
- 229940125681 anticonvulsant agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- -1 phenylC1-4alkyl Chemical group 0.000 claims abstract description 22
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 19
- 239000001257 hydrogen Substances 0.000 claims abstract description 19
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 18
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 18
- 230000001537 neural effect Effects 0.000 claims abstract description 18
- 208000004296 neuralgia Diseases 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 11
- 206010015037 epilepsy Diseases 0.000 claims abstract description 11
- 230000035939 shock Effects 0.000 claims abstract description 11
- 239000012453 solvate Substances 0.000 claims abstract description 10
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
- 206010003591 Ataxia Diseases 0.000 claims abstract description 9
- 206010058019 Cancer Pain Diseases 0.000 claims abstract description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 9
- 206010008748 Chorea Diseases 0.000 claims abstract description 9
- 208000017164 Chronobiology disease Diseases 0.000 claims abstract description 9
- 206010026749 Mania Diseases 0.000 claims abstract description 9
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 9
- 208000026072 Motor neurone disease Diseases 0.000 claims abstract description 9
- 208000002740 Muscle Rigidity Diseases 0.000 claims abstract description 9
- 208000008238 Muscle Spasticity Diseases 0.000 claims abstract description 9
- 208000002193 Pain Diseases 0.000 claims abstract description 9
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 9
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims abstract description 9
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims abstract description 9
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 9
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 229940049706 benzodiazepine Drugs 0.000 claims abstract description 9
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims abstract description 9
- 208000012601 choreatic disease Diseases 0.000 claims abstract description 9
- 229960003920 cocaine Drugs 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 9
- 206010022437 insomnia Diseases 0.000 claims abstract description 9
- 206010027599 migraine Diseases 0.000 claims abstract description 9
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 230000007971 neurological deficit Effects 0.000 claims abstract description 9
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 9
- 229960002715 nicotine Drugs 0.000 claims abstract description 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 208000019906 panic disease Diseases 0.000 claims abstract description 9
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 9
- 208000019116 sleep disease Diseases 0.000 claims abstract description 9
- 208000018198 spasticity Diseases 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 9
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 9
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 9
- 206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 9
- 208000030507 AIDS Diseases 0.000 claims abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 206010036312 Post-traumatic epilepsy Diseases 0.000 claims abstract description 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 8
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 8
- 150000002367 halogens Chemical class 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 8
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims abstract description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims abstract description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims abstract description 3
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- MJUGLNQOKNSWHA-UHFFFAOYSA-N ClC=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.N1=CC(=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.FC(C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F Chemical compound ClC=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.N1=CC(=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.FC(C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F MJUGLNQOKNSWHA-UHFFFAOYSA-N 0.000 claims description 2
- YZBJZBITOFDQCC-UHFFFAOYSA-N ClC=1C=C(C=CC1)NC=1N=NC(=CC1C)C1=CC=CC=C1.COC1=C(C=CC=C1)NC=1N=NC(=CC1)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1.ClC=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1 Chemical compound ClC=1C=C(C=CC1)NC=1N=NC(=CC1C)C1=CC=CC=C1.COC1=C(C=CC=C1)NC=1N=NC(=CC1)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1.ClC=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1 YZBJZBITOFDQCC-UHFFFAOYSA-N 0.000 claims description 2
- QSKSBLQRNPWOTN-UHFFFAOYSA-N N-(2-tert-butylphenyl)-4-phenylphthalazin-1-amine 4-phenyl-N-[2-(trifluoromethoxy)phenyl]phthalazin-1-amine 4-phenyl-N-[3-(trifluoromethoxy)phenyl]phthalazin-1-amine Chemical compound FC(OC1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F.FC(OC=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F.C(C)(C)(C)C1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 QSKSBLQRNPWOTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SENKAFQBJFGLDX-UHFFFAOYSA-N C(#N)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.FC(OC1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F Chemical compound C(#N)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.FC(OC1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F SENKAFQBJFGLDX-UHFFFAOYSA-N 0.000 claims 1
- XSTKPJCVDUWBLN-UHFFFAOYSA-N C(C)OC(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(#N)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound C(C)OC(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(#N)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 XSTKPJCVDUWBLN-UHFFFAOYSA-N 0.000 claims 1
- YOPOKMLKLZJQPU-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.ClC1=C(C(=CC=C1)Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.ClC=1C=C(C=C(C1)Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.ClC1=C(C(=CC=C1)Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.ClC=1C=C(C=C(C1)Cl)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 YOPOKMLKLZJQPU-UHFFFAOYSA-N 0.000 claims 1
- YUBDOOKTKGUGQE-UHFFFAOYSA-N ClC=1C=C(C=CC1)NC1=NN=CC2=CC=CC=C12.ClC=1C=C(C=CC1)NC=1N=NC(=CC1C)C1=CC=CC=C1.COC1=C(C=CC=C1)NC=1N=NC(=CC1)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1 Chemical compound ClC=1C=C(C=CC1)NC1=NN=CC2=CC=CC=C12.ClC=1C=C(C=CC1)NC=1N=NC(=CC1C)C1=CC=CC=C1.COC1=C(C=CC=C1)NC=1N=NC(=CC1)C1=CC=CC=C1.C(C1=CC=CC=C1)(=O)C=1C=C(C=CC1)NC=1N=NC(=CC1)C1=CC=CC=C1 YUBDOOKTKGUGQE-UHFFFAOYSA-N 0.000 claims 1
- NASVJQLZCWUYOR-UHFFFAOYSA-N FC(OC=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F.C(C)(C)(C)C1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound FC(OC=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1)(F)F.C(C)(C)(C)C1=C(C=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 NASVJQLZCWUYOR-UHFFFAOYSA-N 0.000 claims 1
- VZDALJCKGHZTMB-UHFFFAOYSA-N ethyl 3-[(4-phenylphthalazin-1-yl)amino]benzoate 4-phenyl-N-pyridin-3-ylphthalazin-1-amine Chemical compound N1=CC(=CC=C1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1.C(C)OC(=O)C=1C=C(C=CC1)NC1=NN=C(C2=CC=CC=C12)C1=CC=CC=C1 VZDALJCKGHZTMB-UHFFFAOYSA-N 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract description 2
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- 229940126062 Compound A Drugs 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- BEATZJALKXTWKH-UHFFFAOYSA-N n,4-diphenylphthalazin-1-amine Chemical compound N=1N=C(C=2C=CC=CC=2)C2=CC=CC=C2C=1NC1=CC=CC=C1 BEATZJALKXTWKH-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- ZANLYPOJYLCUKK-UHFFFAOYSA-N 3-[(4-phenylphthalazin-1-yl)amino]benzonitrile Chemical compound N#CC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 ZANLYPOJYLCUKK-UHFFFAOYSA-N 0.000 description 2
- YTDZFWNQRRMELI-UHFFFAOYSA-N 6-phenylpyridazin-3-amine Chemical class N1=NC(N)=CC=C1C1=CC=CC=C1 YTDZFWNQRRMELI-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- FZKFYPQKBPUADH-UHFFFAOYSA-N n-(2,3-dichlorophenyl)-4-phenylphthalazin-1-amine Chemical compound ClC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1Cl FZKFYPQKBPUADH-UHFFFAOYSA-N 0.000 description 2
- BBONPPQEVPNUGT-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-4-phenylphthalazin-1-amine Chemical compound ClC1=CC(Cl)=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 BBONPPQEVPNUGT-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RXPBGKAWUYVARM-UHFFFAOYSA-N phenyl-[3-[(4-phenylphthalazin-1-yl)amino]phenyl]methanone Chemical compound C=1C=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=CC=1C(=O)C1=CC=CC=C1 RXPBGKAWUYVARM-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000028500 tonic seizure Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WJJDLSHYLZRFDD-UHFFFAOYSA-N 1-chloro-4-phenylphthalazine Chemical compound C12=CC=CC=C2C(Cl)=NN=C1C1=CC=CC=C1 WJJDLSHYLZRFDD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- XCJLBNVENUPHEA-UHFFFAOYSA-N 4-phenyl-2h-phthalazin-1-one Chemical compound C12=CC=CC=C2C(=O)NN=C1C1=CC=CC=C1 XCJLBNVENUPHEA-UHFFFAOYSA-N 0.000 description 1
- GHAXGSIRRYAGNE-UHFFFAOYSA-N 4-phenyl-n-[2-(trifluoromethoxy)phenyl]phthalazin-1-amine Chemical compound FC(F)(F)OC1=CC=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 GHAXGSIRRYAGNE-UHFFFAOYSA-N 0.000 description 1
- KNYVGNRPDDBAIP-UHFFFAOYSA-N 4-phenyl-n-[3-(trifluoromethyl)phenyl]phthalazin-1-amine Chemical compound FC(F)(F)C1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 KNYVGNRPDDBAIP-UHFFFAOYSA-N 0.000 description 1
- BGTOWRKOZIVQAF-UHFFFAOYSA-N 4-phenyl-n-pyridin-3-ylphthalazin-1-amine Chemical compound N=1N=C(C=2C=CC=CC=2)C2=CC=CC=C2C=1NC1=CC=CN=C1 BGTOWRKOZIVQAF-UHFFFAOYSA-N 0.000 description 1
- GLHCKIVVETUBAN-UHFFFAOYSA-N 4-phenylphthalazin-1-amine Chemical class C12=CC=CC=C2C(N)=NN=C1C1=CC=CC=C1 GLHCKIVVETUBAN-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CEHQLKSLMFIHBF-UHFFFAOYSA-N N-(3-chlorophenyl)-4-phenyl-1-phthalazinamine Chemical compound ClC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 CEHQLKSLMFIHBF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- UKNRDOYFRWGXIK-UHFFFAOYSA-N ethyl 3-[(4-phenylphthalazin-1-yl)amino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 UKNRDOYFRWGXIK-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JZIYHDQZSVSQRK-UHFFFAOYSA-N n-(2,3-dichlorophenyl)-4-phenylphthalazin-1-amine;n-(3-ethylphenyl)-4-phenylphthalazin-1-amine Chemical compound CCC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1.ClC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1Cl JZIYHDQZSVSQRK-UHFFFAOYSA-N 0.000 description 1
- SIQOFGFJLHIZLO-UHFFFAOYSA-N n-(2,3-dimethylphenyl)-4-phenylphthalazin-1-amine Chemical compound CC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1C SIQOFGFJLHIZLO-UHFFFAOYSA-N 0.000 description 1
- YRVVHYOAFHMGNB-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-4-phenylphthalazin-1-amine Chemical compound ClC1=CC=CC(Cl)=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 YRVVHYOAFHMGNB-UHFFFAOYSA-N 0.000 description 1
- AJILKKQHKCETQO-UHFFFAOYSA-N n-(2-chlorophenyl)-4-phenylphthalazin-1-amine Chemical compound ClC1=CC=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 AJILKKQHKCETQO-UHFFFAOYSA-N 0.000 description 1
- HLOSHYFQAMAVLU-UHFFFAOYSA-N n-(2-ethylphenyl)-4-phenylphthalazin-1-amine Chemical compound CCC1=CC=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 HLOSHYFQAMAVLU-UHFFFAOYSA-N 0.000 description 1
- OAGHRJHAUUWGRV-UHFFFAOYSA-N n-(2-methoxyphenyl)-6-phenylpyridazin-3-amine Chemical compound COC1=CC=CC=C1NC1=CC=C(C=2C=CC=CC=2)N=N1 OAGHRJHAUUWGRV-UHFFFAOYSA-N 0.000 description 1
- QJBAZUMMVKISSM-UHFFFAOYSA-N n-(2-tert-butylphenyl)-4-phenylphthalazin-1-amine Chemical compound CC(C)(C)C1=CC=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 QJBAZUMMVKISSM-UHFFFAOYSA-N 0.000 description 1
- DIESCXTYJZOHSB-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-4-phenylphthalazin-1-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 DIESCXTYJZOHSB-UHFFFAOYSA-N 0.000 description 1
- ULCVUFCBLSISED-UHFFFAOYSA-N n-(3-chlorophenyl)-4-methyl-6-phenylpyridazin-3-amine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NC1=CC=CC(Cl)=C1 ULCVUFCBLSISED-UHFFFAOYSA-N 0.000 description 1
- UDFPXGXGVRAUBU-UHFFFAOYSA-N n-(3-chlorophenyl)-6-phenylpyridazin-3-amine Chemical compound ClC1=CC=CC(NC=2N=NC(=CC=2)C=2C=CC=CC=2)=C1 UDFPXGXGVRAUBU-UHFFFAOYSA-N 0.000 description 1
- FFFDPQUJMGZELA-UHFFFAOYSA-N n-(3-chlorophenyl)phthalazin-1-amine Chemical compound ClC1=CC=CC(NC=2C3=CC=CC=C3C=NN=2)=C1 FFFDPQUJMGZELA-UHFFFAOYSA-N 0.000 description 1
- ZYMZBSLZRNUXLG-UHFFFAOYSA-N n-(3-ethylphenyl)-4-phenylphthalazin-1-amine Chemical compound CCC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 ZYMZBSLZRNUXLG-UHFFFAOYSA-N 0.000 description 1
- LZADJUJGYOEGTQ-UHFFFAOYSA-N n-(3-fluorophenyl)-4-phenylphthalazin-1-amine Chemical compound FC1=CC=CC(NC=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)=C1 LZADJUJGYOEGTQ-UHFFFAOYSA-N 0.000 description 1
- AAUGIQYXZOLAEN-UHFFFAOYSA-N n-(4-chlorophenyl)-4-phenylphthalazin-1-amine Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 AAUGIQYXZOLAEN-UHFFFAOYSA-N 0.000 description 1
- NSMLPKMOJGYBDS-UHFFFAOYSA-N n-(4-fluorophenyl)-4-phenylphthalazin-1-amine Chemical compound C1=CC(F)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 NSMLPKMOJGYBDS-UHFFFAOYSA-N 0.000 description 1
- VUCQDHXWTYYKML-UHFFFAOYSA-N n-(4-tert-butylphenyl)-4-phenylphthalazin-1-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 VUCQDHXWTYYKML-UHFFFAOYSA-N 0.000 description 1
- RBAQOAYHTJXKRR-UHFFFAOYSA-N n-phenylpyridazin-3-amine Chemical class C=1C=CN=NC=1NC1=CC=CC=C1 RBAQOAYHTJXKRR-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000216 proconvulsive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical class NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne un procédé de traitement ou de prophylaxie des maladies ou troubles suivants: anxiété, manie, dépression, troubles paniques ou comportement agressif, troubles associés à une hémorragie sous-arachnoïdienne ou à un choc nerveux, effets associés au sevrage de substances donnant lieu à des abus telles que cocaïne, nicotine, alcool et benzodiazépines, troubles pouvant être traités ou prévenus avec des agents anti-convulsifs tels que épilepsie incluant l'épilepsie post-traumatique, maladie de Parkinson, psychose, migraine, ischémie cérébrale, maladie d'Alzheimer et autres maladies dégénératives telles que chorée de Huntington, schizophrénie, troubles obsessionnels-compulsifs, déficits neurologiques associés au SIDA, troubles du sommeil (incluant troubles du rythme circadien, insomnie et narcolepsie), tics (maladie de Gilles de la Tourette, par exemple), lésion traumatique du cerveau, acouphène, névralgie, en particulier névralgie faciale, douleur névropathique, douleur dentaire, douleur cancéreuse, activité nerveuse inappropriée causant des neurodysthésies dans des maladies telles que diabète, sclérose en plaques et maladie du motoneurone, ataxies, rigidité musculaire (hypertonie spastique), dysfonction temporo-mandibulaire et sclérose latérale amyotrophique. Ce procédé comprend l'administration à la personne souffrante en ayant besoin d'une quantité active ou prophylactique d'un composé de formule (I) ou d'un sel ou solvate acceptable pharmaceutiquement de ce composé. Dans la formule (I), le système cyclique Q représente pyridazinyle ou phtalazinyle, le système cyclique P représente phényle ou pyridyle, R?1¿ représente hydrogène, alkyle C¿1-6?, phényle ou alkyle C¿1-6? phényle, R?2¿ représente hydrogène ou alkyle C¿1-6?, R?3¿ représente hydrogène ou jusqu'à trois substituants sélectionnés dans le groupe halogène, CN, trifluorométhyle, trifluorométhoxy, alkyle C¿1-6?, alcoxy C¿1-6?, alkyle C¿1-6? carbonyle, alcoxy C¿1-6? carbonyle, phényle, phénoxy, phénylalkyle C¿1-4?, benzyloxy ou benzoyle.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9707693.9A GB9707693D0 (en) | 1997-04-16 | 1997-04-16 | Novel method of treatment |
| GB9707693.9 | 1997-04-16 | ||
| PCT/EP1998/002172 WO1998046574A1 (fr) | 1997-04-16 | 1998-04-14 | Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2288171A1 true CA2288171A1 (fr) | 1998-10-22 |
Family
ID=10810873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002288171A Abandoned CA2288171A1 (fr) | 1997-04-16 | 1998-04-14 | Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0975605A1 (fr) |
| JP (1) | JP2001518908A (fr) |
| CA (1) | CA2288171A1 (fr) |
| GB (1) | GB9707693D0 (fr) |
| WO (1) | WO1998046574A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207666B1 (en) * | 1995-06-07 | 2001-03-27 | Cell Pathways, Inc. | Method for treating a patient having precancerous lesion with 4-phenylphthalazine derivatives |
| US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
| GB0310726D0 (en) | 2003-05-09 | 2003-06-11 | Merck Sharp & Dohme | Therapeutic agents |
| US8592421B2 (en) * | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| CA2589106C (fr) | 2004-11-02 | 2015-07-21 | Northwestern University | Composes pyridazine, compositions et procedes associes et leur utilisation dans le traitement de maladies inflammatoires |
| WO2006050359A2 (fr) | 2004-11-02 | 2006-05-11 | Northwestern University | Composes pyridazine et methodes |
| EP2402318A1 (fr) | 2006-03-31 | 2012-01-04 | Novartis AG | Inhibiteurs de la DGAT |
| CA2650711A1 (fr) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase |
| AU2007243280A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| WO2007127475A2 (fr) * | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur |
| CA2812088A1 (fr) * | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Derives de la phtalazine comme inhibiteurs de jak1 |
| WO2013019938A1 (fr) * | 2011-08-02 | 2013-02-07 | The Brigham And Women's Hospital, Inc. | Dérivés de pyridazine en tant qu'activateurs d'eaat2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2063249A (en) * | 1979-10-09 | 1981-06-03 | Mitsubishi Yuka Pharma | 4-Phenylphthalazine derivatives |
| FR2511366A1 (fr) * | 1981-08-11 | 1983-02-18 | Sanofi Sa | Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent |
| PT93060B (pt) * | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| TW279162B (fr) * | 1991-09-26 | 1996-06-21 | Mitsubishi Chem Corp |
-
1997
- 1997-04-16 GB GBGB9707693.9A patent/GB9707693D0/en active Pending
-
1998
- 1998-04-14 WO PCT/EP1998/002172 patent/WO1998046574A1/fr not_active Ceased
- 1998-04-14 JP JP54349098A patent/JP2001518908A/ja active Pending
- 1998-04-14 CA CA002288171A patent/CA2288171A1/fr not_active Abandoned
- 1998-04-14 EP EP98920520A patent/EP0975605A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0975605A1 (fr) | 2000-02-02 |
| JP2001518908A (ja) | 2001-10-16 |
| WO1998046574A1 (fr) | 1998-10-22 |
| GB9707693D0 (en) | 1997-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2288171A1 (fr) | Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs | |
| KR20010086471A (ko) | 도파민-ｄ3-수용체 친화성을 갖는 트리아졸 화합물 | |
| JP4939720B2 (ja) | ４−（２−フェニルチアゾール−５−イル）−１，４−ジアザビシクロ［３．２．２］ノナン誘導体、それらの製造方法および治療用途 | |
| WO2000007993A1 (fr) | Isoquinoleines substituees et leur utilisation en tant qu'anticonvulsifs | |
| EP1042296B1 (fr) | Derives d'isoquinoline substituee et utilisation de ces derniers comme anticonvulsifs | |
| RS56004A (sr) | Derivati triazolo-kvinolina korisni kao veznici receptora adenozina | |
| US5373015A (en) | Fused pyridine derivatives useful as angiotensin II antagonists | |
| EP0354781B1 (fr) | Composés de benzodiazépine et leur utilisation comme médicaments | |
| BG62403B1 (bg) | Изохинолинови производни в качеството на терапевтичнисредства | |
| US6395759B1 (en) | Substituted benzamide derivatives and pharmaceutical compositions containing them | |
| EP1200409B1 (fr) | Derives d' isoquinoleine substituee et leur utilisation comme anticonvulsants | |
| EP1017694A2 (fr) | Derives de la n-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenyluree | |
| US6245778B1 (en) | 1,6-naphthyridine anti-convulsants | |
| JP2001523678A (ja) | イソキノリン誘導体およびその治療用途 | |
| CA2286452A1 (fr) | Composes de pyrimido-isoquinoline a action anticonvulsive | |
| US6410555B1 (en) | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | |
| JP2003055376A (ja) | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 | |
| JPH01228969A (ja) | ベンゾ〔６，７〕シクロヘプタ〔１，２−ｃ〕ピリダジン化合物およびその医薬用途 | |
| EP1104404A1 (fr) | Derives d'isoquinoline substitues et leur utilisation comme antiepileptiques | |
| NZ240501A (en) | 4- or 5-(2-nitroanilino)thiazole derivatives | |
| MXPA99008627A (en) | Anti-convulsant isoquinolyl-benzamide derivatives | |
| MXPA00012322A (en) | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |